The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
Correspondence
PreviousPrevious
Volume 350:2101-2102 May 13, 2004 Number 20
NextNext

Antiplatelet Therapy for Ischemic Heart Disease

Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

 Sign up for free e-toc
 

This Article
-Full Text
- PDF
-PDA Full Text
-Purchase this article

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited
-E-mail When Letters Appear

More Information
-Related Article
by Lange, R. A.
-PubMed Citation
To the Editor: In their editorial on antiplatelet therapy for ischemic heart disease, Lange and Hillis (Jan. 15 issue)1 assert that in all patients who undergo percutaneous coronary intervention, clopidogrel should be added to aspirin for 9 to 12 months after the procedure, citing the CREDO (Clopidogrel for the Reduction of Events during Observation)2 and PCI-CURE (Clopidogrel in Unstable Angina to Prevent Recurrent Events)3 trials. However, in these trials the benefits of dual antiplatelet therapy after one month were marginal. In the CREDO trial, treatment of 1053 patients with clopidogrel from day 29 until one year after percutaneous coronary intervention . . . [Full Text of this Article]



HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.